SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasogen Inc (NYSE:MEW - TSE:VAS) Immune Modulation Therapies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cal Gary who wrote (17)5/28/2002 12:22:46 PM
From: Cal Gary  Read Replies (1) of 26
 
Vasogen raises $25-million through financing

Vasogen Inc VAS
Shares issued 46,490,000 May 27 close $4.90
Tue 28 May 2002 News Release
Mr. Glenn Neumann reports
VASOGEN COMPLETES FINANCING
Vasogen has closed its offering of 5.15 million common shares at a price of
$4.85 per share for gross proceeds of approximately $25-million. Research
Capital Corporation led the underwriting.
The net proceeds of the offering, together with current cash resources,
will be used to accelerate clinical development in congestive heart
failure, to support continuing research and development programs, and for
general operations. The company's projected cash resources on May 31, 2002,
including proceeds from the offering, are estimated to be $52-million.
WARNING: The company relies upon litigation protection for
"forward-looking" statements.
(c) Copyright 2002 Canjex Publishing Ltd. stockwatch.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News